Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers.

Abstract

Glioblastoma multiforme (GBM), the grade IV astrocytoma, is the most common and aggressive brain tumor in adults. Despite advances in medical management, the survival rate of GBM patients remains poor, suggesting that identification of GBM-specific targets for therapeutic development is urgently needed. Analysis of several glycan antigens on GBM cell lines revealed that eight of 11 GBM cell lines are positive for stage-specific embryonic antigen-4 (SSEA-4), and immunohistochemical staining confirmed that 38/55 (69%) of human GBM specimens, but not normal brain tissue, were SSEA-4(+) and correlated with high-grade astrocytoma. In addition, an SSEA-4-specific mAb was found to induce complement-dependent cytotoxicity against SSEA-4(hi) GBM cell lines in vitro and suppressed GBM tumor growth in mice. Because SSEA-4 is expressed on GBM and many other types of cancers, but not on normal cells, it could be a target for development of therapeutic antibodies and vaccines.

DOI: 10.1073/pnas.1400283111
0100200201520162017
Citations per Year

264 Citations

Semantic Scholar estimates that this publication has 264 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Lou2014StagespecificEA, title={Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers.}, author={Yi-Wei Lou and Pao-Yuan Wang and Shih-Chi Yeh and Po-Kai Chuang and Shiou-Ting Li and Chung-Yi Wu and Kay-Hooi Khoo and Michael Hsiao and Tsui-Ling Hsu and Chi-Huey Wong}, journal={Proceedings of the National Academy of Sciences of the United States of America}, year={2014}, volume={111 7}, pages={2482-7} }